SK-MEL-5

SK-MEL-5 (Melanoma CDX Model) 

The SK-MEL-5 line was derived from a metastatic melanoma lesion. It carries the BRAF V600E mutation, a common driver in melanoma. SK-MEL-5 has been extensively applied in targeted therapy development. Its reproducible growth ensures reliability in translational melanoma research. 

Key Features: 

• Derived from metastatic melanoma. 

• BRAF V600E mutation. 

• Strong MAPK pathway activation. 

• Reliable xenograft tumorigenicity. 

Applications: 
SK-MEL-5 is used in drug discovery targeting BRAF and MEK pathways. Researchers employ it in biomarker validation and resistance mechanism studies. It is a standard melanoma model for preclinical targeted therapy testing. Its defined genetics make it suitable for precision oncology pipelines.